News Formal

Novartis therapy for infant muscle-wasting disease — potentially carrying a record $2 million price tag — is about to hit market

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

Sverige Nyheter Nyheter

Sverige Senaste nytt,Sverige Rubriker

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:

 /  🏆 3. in SE
 

Tack för din kommentar. Din kommentar kommer att publiceras efter att ha granskats.

Permanent fixes = overpriced. Temporary relief with side effects = underpriced. Dont blame big Pharma. Dont blame insurance companies. Blame every person who pays these companies & says 'that's just how it is.' Everyone is free to make their own choices, except those babies.

Sverige Senaste nytt, Sverige Rubriker

Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.

A $2 Million Drug Is About to Hit the MarketA new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price drugs and how insurers pay for it. This should be classified as a human rights violation. I'll take two, please. I don't believe $2 Million is justified. It is Medical Extortion, nothing more!
Källa: WSJ - 🏆 98. / 63 Läs mer »